Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02845960
Other study ID # Southwest Hospital
Secondary ID
Status Recruiting
Phase N/A
First received July 23, 2016
Last updated July 26, 2016
Start date February 2016

Study information

Verified date July 2016
Source Southwest Hospital, China
Contact WEINAN ZENG, Doctor
Phone +8615023100103
Email weinanzeng@163.com
Is FDA regulated No
Health authority China: Health and Family Planning Commission of Chongqing City
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the influence of rapid recovery on sleep quality following total knee replacement surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria:

1. Primary unilateral total knee artropasty;

2. Patients with Knee osteoartritis or Rheumatoid arthritis;

3. Able and willing to provide signed informed consent.

Exclusion Criteria:

1. Simultaneously bilateral total knee artropasty or revision case;

2. Surgical History of the knee joint;

3. Knee joint cavity paracentesis in recent 3 months;

4. Stiffness with knee;

5. Blood coagulation disorders;

6. History of deep venous thrombosis;

7. Concomitant medical problems such as uncontrolled hypertention, severe cardiovascular disorder, chronic obstructive pulmonary disease, liver or renal failure

8. allergic to NSAIDs, opioid analgesics, zolpidem

9. sleep apnea, Parkinson disease, dementia, depression

10. use of sedatives or hypnotics

11. inability to comply with polysomnographic measurement

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Behavioral:
rapid recovery
rapid recovery

Locations

Country Name City State
China Southwest Hospital Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Southwest Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary WOMAC score 1 mounth Yes
Primary GAD-7 1 mounth Yes
Primary PSQI index 1 mounth Yes
Primary Insomnia severity index 1 mounth Yes
Primary polysomnographic measurement 1 mounth Yes
Primary VAS 1 mounth Yes
Primary Range of motion 1 mounth Yes
See also
  Status Clinical Trial Phase
Terminated NCT01682512 - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis Phase 3
Completed NCT00539760 - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers Phase 1
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT01208181 - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) Phase 3
Completed NCT03254810 - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects Phase 1
Completed NCT01711814 - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study Phase 2
Completed NCT03315494 - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers Phase 1
Withdrawn NCT03241446 - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA) Phase 1
Completed NCT02748785 - MTX Discontinuation and Vaccine Response Phase 4
Completed NCT02553018 - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe Phase 3
Active, not recruiting NCT02260778 - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce N/A
Completed NCT02569736 - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed NCT01750931 - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. Phase 2
Withdrawn NCT01204138 - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA Phase 2
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Completed NCT00973479 - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy Phase 3
Completed NCT00975130 - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Phase 3
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT00660647 - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Phase 3
Completed NCT00550446 - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis Phase 2